Reprogramming in the early embryo involves the transformation of adult germ cells into embryonic stem cells through the expression of Yamanaka factors – typically Oct3/4, Sox2, Klf4, and c-Myc. This process resets age-related gene expression changes and removes cell damage. While not capable of repairing everything, it ensures the youthfulness of the embryo despite older parental age.
Partial reprogramming entails brief exposure to Yamanaka factors or other agents to induce their expression indirectly, aiming to rejuvenate gene expression without losing cell function. Various approaches are being developed towards achieving this, with promising preclinical developments showcasing novel applications of reprogramming technologies.
A recent study titled “A Single-Short Partial Reprogramming of the Endothelial Cells decreases Blood Pressure via attenuation of EndMT in Hypertensive Mice” highlights the potential benefits of partial reprogramming in reducing blood pressure and reversing vascular damage in hypertensive individuals. This innovative strategy shows promise in regenerative medicine for combating cardiovascular diseases.
